Understanding non-muscle invasive bladder cancer and its treatment options
Official title: Transcriptomic classification of non-muscle invasive bladder cancer and its clinical and prognostic implication
Funded at Roswell Park Cancer Institute Corp · NIH-10907672 · Data updated 2026-11-12
This study is looking to help people with non-muscle invasive bladder cancer by finding better ways to predict if their cancer might come back and to see who might not do well with the usual treatment, so they can get more personalized care based on their unique tumor traits.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,256,124 |
| NIH project number | 5R01CA257480-03 |
| Project ID | NIH-10907672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-muscle invasive bladder cancer who are undergoing or considering BCG therapy.
✕Less likely to help
Patients with muscle-invasive bladder cancer or those who have not been diagnosed with bladder cancer may not benefit from this research.
What this research studies
This research focuses on improving the management of non-muscle invasive bladder cancer (NMIBC), which is a common form of bladder cancer. It aims to develop tools that can predict the risk of cancer recurrence and identify patients who may not respond well to the standard treatment, Bacillus Calmette-Guerin (BCG) therapy. By analyzing the genetic information of tumors, the study seeks to create a more personalized approach to treatment, ensuring that patients receive the most effective care based on their specific cancer characteristics. This research builds on a large cohort of NMIBC patients to validate its findings.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with non-muscle invasive bladder cancer, potentially reducing recurrence rates and improving overall outcomes.
How similar studies have gone: Previous research has shown promise in using transcriptomic analysis for bladder cancer, but this specific focus on non-muscle invasive cases is relatively novel.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Tang, Li — Roswell Park Cancer Institute Corp
- Study coordinator: Tang, Li
Related research
Other NIH-funded projects on the same topics.
-
Nrf2 in T cells and how it could boost immune power against bladder cancer
A small grant will explore how a T-cell protein called Nrf2 affects muscle-invasive bladder cancer and whether targeting it could help patients respond better to immune therapies.
-
Repurposing spironolactone to treat bladder cancer inside the bladder
Aims to repurpose spironolactone as an intravesical treatment for non-muscle invasive bladder cancer to help prevent recurrence and progression.
-
Body fats and immune signals shaping bladder cancer outlook
This study will look at how body composition and immune/inflammatory states at diagnosis relate to the outlook for people with non-muscle-invasive bladder cancer.
-
Novel combination immunotherapy for non–muscle-invasive bladder cancer
Researchers are testing a new combination approach using a special anti-CD40 antibody with existing bladder cancer therapies to help patients whose NMIBC did not respond to standard BCG treatment.
-
Why some bladder cancers don't respond to BCG treatment
This project will use detailed tissue and genetic tests to look for what makes some non-muscle invasive bladder cancers resist BCG so better treatments can be found for people who don't respond.
-
Salt-based nanomedicine to treat bladder cancer that doesn’t respond to standard BCG therapy
A patient-focused overview of a new salt-based nanoparticle therapy designed to target non-muscle invasive bladder cancer that is resistant to BCG treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.